Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Launched by FONDAZIONE ITALIANA LINFOMI - ETS · Sep 5, 2024

Keywords

ClinConnect Summary

This clinical trial is looking into different ways to treat Cutaneous T-cell Lymphoma (CTCL), which is a type of skin cancer. The goal is to understand how systemic therapies (treatments that affect the whole body) work in real-life situations for patients with CTCL and its subtypes, like Mycosis Fungoides and Sezary Syndrome. Researchers want to gather information about these treatments to help improve care for patients in the future.

To participate in this study, individuals need to be at least 18 years old and have a confirmed diagnosis of CTCL. They should have started a systemic therapy that lasted for at least three months between January 1, 2016, and December 31, 2021. Participants will need to provide their medical records to help researchers gather the necessary information and must agree to join the study by signing a consent form. This trial is currently not yet recruiting participants, but it aims to provide valuable insights into how these treatments are working for patients like you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed diagnosis of CTCL according to the EORTC 2017 update criteria1.
• • Age ≥18 years.
• • Have received first dose of a systemic therapy, lasted at least 3 months, between 1 January 2016 and 31 December 2021.
• • Availability of complete medical records in order to provide protocol required variables
• • Signed written informed consent.
• Exclusion Criteria:
• • Patients not meeting the above-mentioned inclusion criteria.
• • Refuse to sign a written informed consent.